anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This group will be encouraged to perform two aerobic interval training sessions per week for 12 weeks, on their own and not at the exercise training clinic, while receiving digital follow-up support through HelsaMi and exercise guidance through the exercise app. The digital follow-up through HelsaMi will consist of overview of treatment progress and schedule, communication with health care personnel (video consultation or chat up to 2 times per week), notifications reminding them to exercise, exercise diary, questionnaires, and educational content.
Studies have shown that prolonged wearing of disposable particulate respirators may lead to an increase in carbon dioxide (CO2) levels in the dead space of the respirator as well as in the re-breathing of the expired air when wearing it. The increased CO2 levels may result in headaches, increased irritability, and breathing difficulty. In addition, there is some discomfort due to the accumulation of heat and humid air in the dead space of between the respirator and face. Innosparks Pte Ltd (formerly, ST Dynamics) (the Advanced Engineering Centre of ST Engineering) developed a new type of disposable particulate respirator (hereon referred to as AIR+ Smart Mask) that is suitable for use in both adults and children, from ages 7 and above.They also designed an optional accompanying device, the micro-ventilator, which is battery-powered and aims to extract accumulated heat, moisture, and carbon dioxide from within the mask. Innosparks Pte Ltd (formerly, ST Dynamics) have obtained the US National Institute for Occupational Safety and Health (NIOSH) N95 certification for the three sizes of masks without micro-ventilator, and Conformité Européenne's (CE) certification for the following mask specifications:• FFP1 and NIOSH approved N95 for S and M-sized AIR+ Smart Masks without micro ventilator;• FFP2 and NIOSH approved N95 for L-sized mask without micro ventilator;• FFP1 certification for S and M-sized masks with micro-ventilator, and;• FFP2 certification for the L size mask with micro-ventilator.For purposes of this research, both CE and NIOSH markings will be made for the masks trialed.As the masks were developed specifically for school-going children, this study is designed to explore whether the new disposable particulate respirator, which can be attached with a ventilator to vent out expired air within the respirator, is safe and effective for use in healthy children aged 7 to 14 years of age. This is through measuring the variation of carbon dioxide levels in children with and without the AIR+ Smart Mask. End-tidal carbon dioxide pressure (ETCO2) is a good indicator of arterial carbon dioxide pressure (PaCO2) in healthy adults and children, and has been used for continuous direct assessment of PaCO2 in clinical contexts. The normal range of PaCO2 is from 35 - 45 mmHg. As there is a slight margin of difference between ETCO2 and PaCO2 values during measurement of about 1.6 +/- 4.3mmHg, this study defines 30 to 50mmHg as the acceptable range for ETCO2 levels.
Patients received two capsules of placebos per day during 3 years. When the beta-carotene was stopped, they received only one capsule.
OBJECTIVE: At present, due to the lack of early observation methods, the effect of the 'accordion' technique on the treatment of nonunion of the docking site varies greatly. In this study, color Doppler ultrasound was used to observe the docking site's local changes and investigate the relationship between local microenvironment changes and bone healing after the accordion technique.
METHODS: 30 patients with tibial bone transport treated at the Department of Orthopedics, Second Hospital of Shanxi Medical University, from May 2018 to June 2022, were analyzed retrospectively. Paired-sample t-tests were used for data that conformed to a normal distribution, and paired rank-sum tests were used for before-and-after comparisons that did not conform to a normal distribution. There were 26 males and 4 females, aged 47.3 ± 11.7 years. Before bone transport, the defect gap between tibial bone ends was 6.80 ± 3.61 cm. The steps of the accordion technique were as follows: compression for 7 days, ultrasonic study of the microenvironment at the docking site, distraction for 12 days, latency for 7 days, compression for 14 days, then static fixation and radiological study until complete bone healing. Ultrasound was used to detect the size of the hematoma after 7 days of pressure, and the changes in blood flow before and after the 'accordion' operation.
RESULTS: All patients were followed up for 11.9 ± 1.9 months. At the last follow-up, 22 patients achieved bone healing at the docking site after the treatment of the 'accordion' technique. There was a linear negative correlation between the size of the hematoma and the time of bone healing at the docking site (r = -0.639, p < 0.01). According to the Paley healing criteria, 18 of the 22 patients were excellent, and 4 patients were good.
CONCLUSION: Hematoma is necessary for the 'accordion' technique's success in the treatment of nonunion. The size of the hematoma is negatively related to the time of bone healing. The 'accordion' technique can increase the blood flow of tissue around the docking site. Ultrasound can be used to monitor the changes in the microenvironment at the docking site during the 'accordion' technique and guide the exact plan and prognosis of the 'accordion' technique.
Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the "bone trephination" or "soft tissue trephination" groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired.
Genetic forms of focal and segmental glomerulosclerosis (FSGS) often have extra-renal manifestations. This study examined FSGS-associated genes from the Genomics England Renal proteinuria panel for reported and likely ocular features. Thirty-two of the 55 genes (58%) were associated with ocular abnormalities in human disease, and a further 12 (22%) were expressed in the retina or had an eye phenotype in mouse models. The commonest genes affected in congenital nephrotic syndrome (NPHS1, NPHS2, WT1, LAMB2, PAX2 but not PLCE1) may have ocular manifestations . Many genes affected in childhood-adolescent onset FSGS (NPHS1, NPHS2, WT1, LAMB2, SMARCAL1, NUP107 but not TRPC6 or PLCE1) have ocular features. The commonest genes affected in adult-onset FSGS (COL4A3-COL4A5, GLA ) have ocular abnormalities but not the other frequently affected genes (ACTN4, CD2AP, INF2, TRPC6). Common ocular associations of genetic FSGS include cataract, myopia, strabismus, ptosis and retinal atrophy. Mitochondrial forms of FSGS (MELAS, MIDD, Kearn's Sayre disease) are associated with retinal atrophy and inherited retinal degeneration. Some genetic kidney diseases (CAKUT, ciliopathies, tubulopathies) that result in secondary forms of FSGS also have ocular features. Ocular manifestations suggest a genetic basis for FSGS, often help identify the affected gene, and prompt genetic testing. In general, ocular abnormalities require early evaluation by an ophthalmologist, and sometimes, monitoring or treatment to improve vision or prevent visual loss from complications. In addition, the patient should be examined for other syndromic features and first degree family members assessed.
Neurogenic bladder often occurs after pelvic ganglia injury. Its symptoms, like severe urinary retention and incontinence, have a significant impact on individuals' quality of life. Unfortunately, there are currently no effective treatments available for this type of injury. Here, we designed a fiber-enhanced tissue bandage for injured pelvic ganglia. Tight junctions formed in tissue bandages create a mini tissue structure that enhances resistance in an in vivo environment and delivers growth factors to support the healing of ganglia. Strength fibers are similar to clinical bandages and guarantee ease of handling. Furthermore, tissue bandages can be stored at low temperatures over 5 months without compromising cell viability, meeting the requirements for clinical products. A tissue bandage was applied to a male rat with a bilateral major pelvic ganglia crush injury. Compared to the severe neurogenic bladder symptoms observed in the injury and scaffold groups, tissue bandages significantly improved bladder function. We found that tissue bandage increases resistance to mechanical injury by boosting the expression of cytoskeletal proteins within the major pelvic ganglia. Overall, tissue bandages show promise as a practical therapeutic approach for ganglia repair, offering hope for developing more effective treatments for this thorny condition.
Group 6 provides retreatment on an open-label basis for patients of Group 5 who failed treatment. Patients will receive RO5024048 1000mg bid + Pegasys + Copegus for 24 weeks, followed by SOC for 24 weeks.
Our inclusion criteria for the patients are the following: (1) 18 years old or older; (2) currently being treated by a health care provider for a painful musculoskeletal condition; (3) has felt a usual musculoskeletal pain intensity rating of "2" or higher on a "0" to "10" scale over the last 24 hours; (4) has felt extreme pain that completely disappeared; (5) has felt musculoskeletal pain on most days of the last 3 months; (6) chronic musculoskeletal pain has increased and decreased during the last 3 months; and (6) has felt musculoskeletal pain in more than one location on most days of the last 3 months. Our exclusion criterion for the patients is ever employed as a licensed health care provider.
The invention relates to a medicine for treating dysmenorrhea. The medicine is prepared from the following medicinal raw materials in parts by weight: 8 parts of szechuan lovage rhizomes, 9 parts of prepared nutgrass galingale rhizomes, 6 parts of rhizoma corydalis and 9 parts of argy wormwood leaves. The inventor invents the medicine for treating dysmenorrhea according to the knowledge inherited in the family, the main ideas discussed in ancient books and records and the pathological research of modern medicine into gynecological diseases. The szechuan lovage rhizome in the formula of the medicine is pungent, fragrant and warm, and is capable of wandering up to the parietal region and down to the blood system; the nutgrass galingale rhizome has the efficacies of regulating qi, alleviating depression, normalizing menstruation and relieving pain; the rhizoma corydalis has the efficacies of promoting the circulation of qi, relieving pain, promoting the circulation of blood and removing blood stasis; and the argy wormwood leaf has the efficacies of warming meridians, stopping bleeding, eliminating cold and relieving pain. The medicinal raw materials are combined together to take effect to cure dysmenorrhea basically. Clinical experiments show that the medicine provided by the invention can be used for treating dysmenorrhea safely and effectively.
FIELD: medicine. SUBSTANCE: method involves applying local and general therapy. Local therapy involves applying antimycotic remedy like Dyphlucan. General therapy involves applying Nystatin. Gel containing Tyzol and Nystatin in 10 mg Tyzol and 500000 AU Nystatin proportion is additionally applied in local treatment as application to injured area 4-5 times a day after a meal in 7 days long course. The course is repeated when indicated. EFFECT: enhanced effectiveness of treatment course.
PROBLEM TO BE SOLVED: To obtain a new pyridine derivative selectively acting on a peripheral- type benzodiazepine receptor. SOLUTION: This new pyridine derivative is shown by formula I [X is O or NR4 ; R1 is H, an alkyl, etc.; R2 is an alkyl, a cloalkyl or a (substituted) phenyl; R. and R. are each H or a lower alkyl; R5 and R6 are each H, a lower alkyl, etc.; A is a (substituted) phenyl or (substituted) heteroaryl], e.g. N-(4- chlorophenyl)-N-methyl-2 (2,3-dimethyl-6-phenyl-4-pyridyloxy)acetamide. The compound of formula I in which is NR4 is obtained by reaction of a compound of formula II (Z is an eliminable group) with a compound of formula III under normal or a higher pressure in the presence of a base such as sodium carbonate. This new compound is useful as a preventive or therapeutic agent for anxiety- related diseases, depression, central diseases such as epilepsy, and ctirculatory diseases.
PURPOSE:To enable measurement of the amount of a tissue type plasminogen activator (t-PA) antigen, etc., excellent in specific aftinity against antigens by culturing a mouse hybridoma, etc., in a culture medium. CONSTITUTION:The splenic cell of BALB/C strain mouse sensitized with t-PA derived from a human melanoma cell is fused to a mouse myelomatous cell (e.g., P3X63Ag8.U1) to provide (A) a mouse hybridoma clone sp-322, which is then cultured in a culture medium containing bovine fetal blood serum, etc., at about 37 deg.C in a vapor phase of 5wt.% CO2 and about 95wt.% air for 2-4 days to afford a culture. The resultant culture is then dialyzed and purified to isolate a monoclonal antibody having the specificity for the n-PA and following properties. Molecular weight; 153000+ or -10000. IgG subclass) IgG1. L-chain amino acid sequence within the L-chain variable region; amino acid sequence expressed by the formula. Binding part to antigen; part with affinity for fibrin or vicinity thereof, etc.
Participants were given irinotecan at a fixed dose: \[350 mg/m2 in patients either not on anti-seizure drugs or on anti-seizure drugs which do not interfere with the metabolism of Irinotecan; 600 mg/m2 in patients on anti-seizure drugs which interfere with the metabolism of Irinotecan\] once every 21 days. Depending on how many side effects were experienced with the first cycle \[first 21 days\], the dose of both drugs may remain the same or may be decreased to make the treatment better tolerated with less side effects. The irinotecan was given to through a vein over 90 minutes.
This invention provides a preparing method of the Chinese traditional medicinal composition granules for treating galactophore disease. The method consists of the following steps: (1)Take tangerine leafs, radices salviae, Chinese honeylocust, cowherb seed, Chinaberry fruit and earthworm. (2)Fry the tangerine leafs, radices salviae, Chinese honeylocust, cowherb seed,, Chinaberry fruit in water separately, combine the fried liquids, filter them and have the filtered liquid concentrated. (3)Add earthworm to concentrated liquid obtained in step (2), mix it even. (4)Use 60-90% ethanol to abstract the concentrated liquid obtained in step (3), filter the abstracted liquid, reclaim ethanol and concentrate it till it forms into thick cream. (5)Add one or manifold of the following ingredients: cane sugar, lactose, xylitol and tangerine sugar, add an amount of starch, starch gum, then mix them even, boil to make them into the form of granules. The method is easy operated with low production costs and high efficiency. This invention also provides a kind of the Chinese traditional medical granules made by the above preparing method.
Any myofascial release or exercise program will not be applied to the participants in the control group. The first evaluation of the participants will be made before other groups starting the 4-week program. Final assessments will be made within 2-3 days after the other groups 4-week training ends. Evaluations will include flexibility measurements, muscular endurance measurements, balance evaluations.
BACKGROUND: PHACTR1 (phosphatase and actin regulators) plays a key role in cortical migration and synaptic activity by binding and regulating G-actin and PPP1CA. This study aimed to expand the genotype and phenotype of patients with de novo variants in PHACTR1 and analyse the impact of variants on protein-protein interaction.
METHODS: We identified seven patients with PHACTR1 variants by trio-based whole-exome sequencing. Additional two subjects were ascertained from two centres through GeneMatcher. The genotype-phenotype correlation was determined, and AlphaFold-Multimer was used to predict protein-protein interactions and interfaces.
RESULTS: Eight individuals carried missense variants and one had CNV in the PHACTR1. Infantile epileptic spasms syndrome (IESS) was the unifying phenotype in eight patients with missense variants of PHACTR1. They could present with other types of seizures and often exhibit drug-resistant epilepsy with a poor prognosis. One patient with CNV displayed a developmental encephalopathy phenotype. Using AlphaFold-Multimer, our findings indicate that PHACTR1 and G-actin-binding sequences overlap with PPP1CA at the RPEL3 domain, which suggests possible competition between PPP1CA and G-actin for binding to PHACTR1 through a similar polymerisation interface. In addition, patients carrying missense variants located at the PHACTR1-PPP1CA or PHACTR1-G-actin interfaces consistently exhibit the IESS phenotype. These missense variants are mostly concentrated in the overlapping sequence (RPEL3 domain).
CONCLUSIONS: Patients with variants in PHACTR1 can have a phenotype of developmental encephalopathy in addition to IESS. Moreover, our study confirmed that the variants affect the binding of PHACTR1 to G-actin or PPP1CA, resulting in neurological disorders in patients.
For Hispanic/Latino families in the United States (U.S.), care for a loved one with dementia is provided largely by family caregivers. Evidence-based resources that support and engage family caregivers are critical to improving care and outcomes for persons living with dementia and improving the wellness of their family caregiver. However, access to these vital resources is limited for Hispanic/Latino families in the U.S. To address health disparities in dementia care for Hispanic/Latino families in the U.S., the investigators are developing an approach for deploying the proven Caregiver-Enabled Care Program (CECP) to Spanish-speaking caregivers of patients with dementia. For this study, the investigators will enroll 135 Spanish-speaking family caregiver/dementia-patient dyads living in the U.S. who are participants in a Program for All-Inclusive Care for the Elderly (PACE) or dementia support network or provider. Participation for each caregiver enrolled in the study involves engaging in the Spanish-language CECP for 6 months. The overall duration of the research project is 12 months.

At the conclusion of the study, the investigators expect to show that the highly- scalable approach using Artificial Intelligence (AI) plus human validation provides a Spanish-language CECP that can achieve comparable engagement of the proven English-language CECP. The investigators will measure differences in how Spanish-speaking caregivers engage in education, coaching, and assessments compared to the engagement of English-speaking caregivers. Understanding these differences will allow the investigators to explore potential cultural differences in user engagement and inform future optimization of the program. This Phase 1 Small Business Innovation Research (SBIR) study is supported by the National Institute On Aging (NIA) of the National Institutes of Health (NIH) under Award Number R43AG088143.
PROBLEM TO BE SOLVED: To prepare an antimicrobial agent, having ultrahigh antimicrobial activities against periodontotic bacteria, dental cariogenic bacteria and nosocomial infection without any effects on human bodies and having high safety by purifying an extract from a tree bark of a mulberry with a hydrophilic organic solvent. SOLUTION: This antimicrobial agent comprises any compound represented by formulae I to V as an active ingredient. The compound is preferably prepared by extracting a tree bark of, e.g. a plant belonging to the genus Morus, concretely Morus bombycis Koidz.) with a nonpolar solvent such as hexane, defatting the plant, then extracting the plant with a lower fatty acid ester, a lower alcohol, an ether or a ktone, vacuum concentrating the resultant extract, providing an extract of the tree bark of the plant belonging to the genus, treating the extract by adsorption column chromatography and reversed phase column chromatography, affording a crude product and further purifying the crude product according to high-performance liquid chromatography(HPLC).  The compound represented by formula I is preferably mulberrofuran G and the compound represented by formula II is preferably mulberrofuran D. The compound represented by formula III is preferably kuwanol A and the compound represented by formula IV is preferably mulberrofuran C. The compound represented by formula V is preferably sanggenone G.
Very few literatures reported the clinical use of microbiota or bacteria for Autism Spectrum Disorder. The most effective strategy for reconstruction of gut microbiota should be fecal microbiota transplantation (WMT). Washed microbiota transplantation (WMT) can significantly reduce FMT-related AEs by removing parasite eggs, fecal particles, and fungi through a series of automated washing procedures. This study aims to evaluate the efficacy and safety of FMT for ASD. Patients received repeated WMT with fecal from healthy donors. Microbiota analysis will also be performed on both the donor and recipient stool sample prior to transplantation, and on the recipient sample at 3 month post transplantation. This study sought to evaluate the efficacy of washed microbiota transplantation (WMT) in children with ASD and explore the role of washed bacteria transplantation in improving ASD symptoms.
FIELD: medicine. ^ SUBSTANCE: invention relates to veterinary science. The method involves a hypodermic injection of a hyperimmune serum containing specific PG-3, IRT and VD-MD virus antibodies every 24 hours to clinical recovery. It is combined with intake of 70% alcoholate of grinded herbal mixture containing equal proportions of purple echinacea herb and blossom clusters, Syrian rue herb, tillet blossom and common licorice roots. The mixture is prepared in the raw material to extractant relation 1:10, kept at temperature 18-20C for 7 days. It is presented as 7-8% aqueous solution to be introduced in animals in dosage 2.5-3.5 ml/kg of live weight every 12 hours to clinical recovery. ^ EFFECT: method provides correction of the key broken components of immune system and enhancement of the natural resistance. ^ 4 tbl, 2 ex
The invention provides a forest leech antithrombotic polypeptide Sylvestin and an in-vitro expression preparation method thereof, belonging to the technical field of polypeptide synthesis expression, wherein the amino acid sequence of the polypeptide Sylvestin is shown in Seq ID No. 1. The invention also provides a modified peptide of the polypeptide Sylvestin, and the amino acid sequence of the modified peptide is shown as Seq ID No.5, Seq ID No.6, Seq ID No.7 or Seq ID No. 8. The polypeptide Sylvestin and the modified peptide thereof have FXIIa inhibitory activity, and have the effects of resisting thrombus and treating stroke. The in vitro expression preparation method of the invention realizes the large-scale and low-cost production of the leech Sylvestin polypeptide in a prokaryotic organism, and is applied to the preparation of biological functional drugs through purification.
PURPOSE: A cosmetic composition containing oil tackifier, antioxidant, pigment, and natural aroma oil is provided to suppress appetite by stimulating satiety center. CONSTITUTION: A cosmetic composition suppresses appetite by containing hydrocarbons composite polymer containing butane or isobutene as a monomer, oil tackifier, antioxidant, pigment, and natural aroma oil. The natural aroma oil is contained 0.05-0.5 weight% based on total composition. The natural aroma oil is grapefruits, peppermint, rosemary, lavender, sandalwood, geranium, and bergamot. The cosmetic composition is makeup cosmetic, skin, lotion, essence, liquid cream, and foundation. The oil tackifier is dextrin fatty acid ester, stearoryl inulin, polyethylene, or polygyceryl fatty acid ester.